The nephrology landscape continues to evolve1
Hemoglobin (Hb) levels in 2011 and 20142
Data are from OutcomesPlus, a national database of clinical data from patients receiving dialysis in facilities across the United States, excluding hospital and governmental entity patients. It contains information on approximately 80% to 85% of the entire US dialysis population. Subjects were categorized based on their mean Hb measurement during the first quarter.
IMPORTANT SAFETY INFORMATIONWARNING - Chronic Kidney Disease:
- In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
- No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
- Use the lowest EPOGEN® dose sufficient to reduce the need for red blood cell (RBC) transfusions.
Scroll down for additional Important Safety Information